1.The board shall adopt rules in accordance with chapter 17A to carry out the purposes
of, and to enforce the provisions of, this subchapter. The rules shall include but not be limited
to the development of procedures relating to:
a.Identifying each patient about whom information is entered into the program.
b.An electronic format for the submission of information from pharmacies and
prescribing practitioners.
c.A waiver to submit information in another format for a pharmacy or prescribing
practitioner unable to submit information electronically.
d.An application by a pharmacy or prescribing practitioner for an extension of time for
transmitting information to the program.
e.Thesubmissionbyanauthorizedrequestorofarequestforinformationandaprocedure
for the verification of the identit
Free access — add to your briefcase to read the full text and ask questions with AI
1. The board shall adopt rules in accordance with chapter 17A to carry out the purposes
of, and to enforce the provisions of, this subchapter. The rules shall include but not be limited
to the development of procedures relating to:
a. Identifying each patient about whom information is entered into the program.
b. An electronic format for the submission of information from pharmacies and
prescribing practitioners.
c. A waiver to submit information in another format for a pharmacy or prescribing
practitioner unable to submit information electronically.
d. An application by a pharmacy or prescribing practitioner for an extension of time for
transmitting information to the program.
e. Thesubmissionbyanauthorizedrequestorofarequestforinformationandaprocedure
for the verification of the identity of the requestor.
f. Use by the board or advisory committee of the program request records required by
section 124.553, subsection 2, to document and report statistical information.
g. Including all schedule II, schedule III, and schedule IV controlled substances, schedule
V controlled substances including when dispensed by a pharmacist without a prescription
except for sales of pseudoephedrine that are reported to the real-time electronic repository,
opioid antagonists, and other prescription substances that the advisory committee and board
determine can be addictive or fatal if not taken under the proper care and direction of a
prescribing practitioner.
h. Access by a pharmacist or prescribing practitioner to information in the program
pursuant to a written agreement with the board.
i. The correction or deletion of erroneous information in the program.
j. The issuance annually of a prescribing practitioner activity report compiled from
information from the program pursuant to subsection 3.
k. The establishment of thresholds or other criteria or measures to be used in identifying
anat-riskpatientasprovidedinsection124.553,subsection1,paragraph“g”,andthetargeted
distribution of proactive notifications suggesting review of the patient’s prescription history.
2. Beginning February 1, 2021, and annually by February 1 thereafter, the board shall
present to the general assembly and the governor a report prepared consistent with section
124.555, subsection 3, paragraph “d”, which shall include but not be limited to the following:
a. The cost to the state of implementing and maintaining the program.
b. Information from pharmacies, prescribing practitioners, the board, the advisory
committee, and others regarding the benefits or detriments of the program.
c. Information from pharmacies, prescribing practitioners, the board, the advisory
committee, and others regarding the board’s effectiveness in providing information from
the program.
3. a. Annually by February 1, the board shall electronically, and at as low a cost as
possible, issue each prescribing practitioner who prescribed a controlled substance reported
to the program as dispensed in the preceding calendar year in this state a prescribing
practitioner activity report which shall include but not be limited to the following:
(1) A summary of the prescribing practitioner’s history of prescribing controlled
substances.
(2) A comparison of the prescribing practitioner’s history of prescribing controlled
substances with the history of other prescribing practitioners of the same profession or
specialty.
(3) The prescribing practitioner’s history of program use.
(4) General patient risk factors.
(5) Educational updates.
(6) Other pertinent information identified by the board by rule.
b. Information provided to a prescribing practitioner in a report required under this
subsectionisprivilegedandshallbekeptconfidentialpursuanttosection124.553, subsection
3.